Search This Blog

Wednesday, November 6, 2019

Nektar Therapeutics EPS beats by $0.17, beats on revenue

Nektar Therapeutics (NASDAQ:NKTR): Q3 GAAP EPS of -$0.56 beats by $0.17.
Revenue of $29.2M (+5.2% Y/Y) beats by $2.78M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)